Migration inhibitory activity in serum and cell supernatants in patients with Sezary syndrome.
Migration inhibitory activity in serum and cell supernatants in patients with Sezary syndrome.
复制标题
塞扎里综合征患者血清和细胞上清液中的迁移抑制活性。
DOI：
10.4049/jimmunol.114.3.915
复制
发表时间：
1975
影响因子：
4.4
通讯作者：
I. Green
中科院分区：
文献类型：
--
作者：
Takeshi Yoshida;R. Edelson;Stanley N. Cohen;I. Green
Sezary综合征患者异常淋巴细胞在体外和体内均产生巨噬细胞迁移抑制因子（macrophage migration inhibitory factor， MIF）。研究的6个个体中有5个具有显著的血清MIF活性，1个具有临界活性。相比之下，在这项研究中，47名正常人和10名除Sezary综合征外的广泛皮肤病患者中的9名没有这种活动。由于Sezary综合征患者的肿瘤T细胞定位于皮肤，它们在该部位产生的化学介质可能是该疾病中所见的全身性剥脱性红皮病的原因。
The abnormal lymphocytes from patients with the Sezary syndrome produce macrophage migration inhibitory factors (MIF) both in vitro and in vivo. Five of six individuals studied had significant serum MIF activity and one had borderline activity. In contrast, in this study 47 normal individuals and 9 of 10 patients with extensive skin disease other than that of the Sezary syndrome had no such activity. Since the neoplastic T cells in patients with the Sezary syndrome localize in the skin, their production of chemical mediators in that site may be responsible for the generalized exfoliative erythroderma seen in that disease.